Scholarlink

<p>High-intensity focused ultrasound (HIFU) combined with chemotherapy has shown considerable promise in treating solid tumours. However, improving tumour ablation efficiency remains a major challenge due to multidrug resistance and lack of tumour selectivity. To solve this problem, we cleverly combine tumour-targeting anaerobic bacteria and hypoxia-activating prodrugs based on tumour hypoxia characteristics. Specifically, we first fabricated a novel platform utilizing cationic liposomes, functionalized with polyethylene glycol (PEG), that encapsulates hypoxia-activated prodrug tirapazamine (TPZ) and the HIFU synergist perfluorohexane (PFH), and these nanoparticles were combined with <i>Bifidobacterium bifidum</i> (<i>B. bifidum</i>) via electrostatic adsorption to fabricate a tumour-targeting system. We leveraged the advantages of <i>B. bifidum</i> that not only mediated nanoparticles effectively reach the tumour to realize better targeted synergistic therapy, but also induce hypoxia in tumorsby themselves in turn amplified the antitumour effect of TPZ. In vitro and in vivo experiments indicate that this strategy effectively promotes tumour cell apoptosis, inhibits tumour growth, and achieves ultrasound imaging. This therapy strategy holds great promise for cancer therapy and highlights the potential of using a combination of bacteria plus nanomedicine in future solid tumour therapy.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bacteria-triggered liposomes for synergistic tumour therapy based on the hypoxic microenvironment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月9日

查看全文
  • Lu Wang,
  • Fujie Jiang,
  • Chang Ding,
  • Xiaoming Wu,
  • Xinqi Xiao,
  • Guifang Dong,
  • Qianmei Yang,
  • Jianzhong Zou,
  • Chun Chen

摘要

High-intensity focused ultrasound (HIFU) combined with chemotherapy has shown considerable promise in treating solid tumours. However, improving tumour ablation efficiency remains a major challenge due to multidrug resistance and lack of tumour selectivity. To solve this problem, we cleverly combine tumour-targeting anaerobic bacteria and hypoxia-activating prodrugs based on tumour hypoxia characteristics. Specifically, we first fabricated a novel platform utilizing cationic liposomes, functionalized with polyethylene glycol (PEG), that encapsulates hypoxia-activated prodrug tirapazamine (TPZ) and the HIFU synergist perfluorohexane (PFH), and these nanoparticles were combined with Bifidobacterium bifidum (B. bifidum) via electrostatic adsorption to fabricate a tumour-targeting system. We leveraged the advantages of B. bifidum that not only mediated nanoparticles effectively reach the tumour to realize better targeted synergistic therapy, but also induce hypoxia in tumorsby themselves in turn amplified the antitumour effect of TPZ. In vitro and in vivo experiments indicate that this strategy effectively promotes tumour cell apoptosis, inhibits tumour growth, and achieves ultrasound imaging. This therapy strategy holds great promise for cancer therapy and highlights the potential of using a combination of bacteria plus nanomedicine in future solid tumour therapy.

Graphical Abstract